Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023 07:00 ET
|
Avalo Therapeutics
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration...
Avalo to Participate in SVB Securities Therapeutics Forum
July 06, 2023 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023 07:00 ET
|
Avalo Therapeutics
AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated...
Avalo to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023 07:00 ET
|
Avalo Therapeutics
Avalo’s SAB is comprised of key opinion leaders in immunology and the LIGHT-signaling network WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:...
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023 16:01 ET
|
Avalo Therapeutics
Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Disclosed cash of approximately $16.7 million as of March 31, 2023 ...
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023 07:30 ET
|
Avalo Therapeutics
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023Disclosed cash of approximately $13 million as of...
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
March 07, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will...